In a significant development for dental health, Japanese researchers have made strides in developing a drug that could potentially enable humans to regrow their teeth. The drug, which suppresses the uterine sensitization-associated gene-1 (USAG-1) protein responsible for inhibiting tooth regrowth, is set to undergo its first human trial at Kyoto University Hospital.

According to reports from Popular Mechanics, earlier tests conducted on ferrets and mice revealed that the drug was effective in promoting tooth regrowth without any notable side effects. Encouraged by these results, the researchers are now poised to move forward with human trials starting from September 2024, expected to conclude by August 2025.

The initial trial will involve 30 men between the ages of 30 and 64 who are currently missing at least one molar tooth. If successful, the study will then expand to individuals with partial edentulism, encompassing those who are missing one to five permanent teeth. Furthermore, there are plans to extend the research to include children aged 2 to 7 who are missing at least four teeth.

Lead researcher Katsu Takahashi, who serves as the head of dentistry and oral surgery at Kitano Hospital, expressed his team's dedication to assisting those who suffer from tooth loss or absence. While permanent solutions for tooth regrowth have been elusive thus far, Takahashi highlights the high expectations people have when it comes to tooth growth.

If the trial proves effective, the breakthrough drug could potentially be available commercially as early as 2030. This would bring hope to millions of individuals globally who currently face dental issues and rely on treatments such as implants or dentures.

The prospect of regenerating teeth through medical intervention marks a significant advancement in the field of dentistry and offers a glimpse into a future where tooth loss can be treated more effectively. As researchers work diligently towards developing viable solutions, the dentistry community and people worldwide eagerly await the outcome of these crucial trials.

(Note: This article has been written based on the information provided by the user and does not contain any additional details beyond what was included in the original context.